title: Bexarotene is a new treatment option for lymphomatoid papulosis.
abstract: BACKGROUND
  Lymphomatoid papulosis (LyP) is a clonal T cell proliferation with large cell histology, a chronic course, and an increased risk of lymphoma. Bexarotene (Targretin) is an RXR-selective retinoid (rexinoid) approved for the cutaneous manifestations of cutaneous T cell lymphoma.
  
  
  OBJECTIVE
  To determine whether bexarotene is effective in treating LyP.
  
  
  METHODS
  Ten patients with chronic and symptomatic LyP were prospectively treated with oral (n = 3) or topical gel (n = 7) formulations of bexarotene.
  
  
  RESULTS
  A favorable response to bexarotene treatment with decreased numbers or duration of lesions was seen in all with objective responses in 8 patients.
  
  
  CONCLUSIONS
  Bexarotene may be an effective palliative treatment for LyP, warranting further controlled studies.
authors.affiliation: Division of Internal Medicine, Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Tex 77030-3597, USA.
authors.forename: Richard A
authors.initials: RA
authors.lastname: Krathen
authors.forename: Staci
authors.initials: S
authors.lastname: Ward
authors.forename: Madeleine
authors.initials: M
authors.lastname: Duvic
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D000368:Aged; D016588:Anticarcinogenic Agents / Q000008:administration & dosage*; D000077610:Bexarotene; D005260:Female; D006801:Humans; D017731:Lymphomatoid Papulosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D011446:Prospective Studies; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage*
chemical_list: D016588:Anticarcinogenic Agents; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene